A U.S. cannabis company has made an offer to acquire Aurora Cannabis Inc., prompting the Edmonton-based firm to form a special committee to review the bid. Curaleaf Holdings Inc. unveiled its proposal to purchase all shares of Aurora, aiming to create a combined cannabis entity with a presence in 17 countries worldwide.
Curaleaf, based in Stamford, Conn., publicly disclosed its bid on the Toronto Stock Exchange after unsuccessful private negotiations with Aurora’s leadership. Despite sending formal letters on June 23 and July 7, outlining the proposal and financial terms, Aurora claimed that it did not receive details on the cash and share components of the offer.
In response, Aurora denied Curaleaf’s assertion that it declined to engage, stating that their lead independent director had been in recent correspondence with Curaleaf’s CEO. Aurora plans to convene a special committee of independent directors to evaluate the bid’s potential benefits for stakeholders, emphasizing that a deal is not guaranteed.
While acknowledging Curaleaf’s interest, analysts caution that the current offer undervalues Aurora’s business potential. They highlight Aurora’s market leadership, product quality, financial strength, and global regulatory expertise as factors that could deliver greater long-term value.
Curaleaf believes that merging the companies would leverage its global distribution reach with Aurora’s medical cannabis franchise and production capabilities, aiming to realize significant revenue synergies. The proposed acquisition is expected to generate substantial annual cost savings and provide Aurora shareholders with enhanced exposure to U.S. regulatory opportunities.